CLINICAL VALIDATION OF THE SPECIALIZED PARTICULATE CONTROL ENVIRONMENTAL EXPOSURE UNIT (SPAC-EEU) FOR CAT DANDER EXPOSURE

IF 5.8 2区 医学 Q1 ALLERGY Annals of Allergy Asthma & Immunology Pub Date : 2024-10-25 DOI:10.1016/j.anai.2024.08.079
L. Hossenbaccus, S. Garvey, T. Walker, H. Botting, L. Steacy, A. Ellis
{"title":"CLINICAL VALIDATION OF THE SPECIALIZED PARTICULATE CONTROL ENVIRONMENTAL EXPOSURE UNIT (SPAC-EEU) FOR CAT DANDER EXPOSURE","authors":"L. Hossenbaccus,&nbsp;S. Garvey,&nbsp;T. Walker,&nbsp;H. Botting,&nbsp;L. Steacy,&nbsp;A. Ellis","doi":"10.1016/j.anai.2024.08.079","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>The Specialized Particulate Control Environmental Exposure Unit (SPaC-EEU) is a controlled allergen challenge facility that has recently undergone a successful technical validation for cat dander exposure, specifically <em>Felis domesticus</em> 1 (Fel d 1). We subsequently performed a clinical validation with cat-allergic and non-allergic participants.</div></div><div><h3>Methods</h3><div>Recruited participants attended a screening visit where eligibility was assessed. Successfully screened cat-allergic and non-allergic participants subsequently attended one of two 3-hour cat dander exposure sessions in the SPaC-EEU. Fel d 1 concentrations were determined using a Fel d 1-specific ELISA. Participants recorded symptom scores at 18 timepoints, between baseline and 24 hours post-onset of allergen exposure.</div></div><div><h3>Results</h3><div>Forty-five participants completed this study, 31 cat-allergics and 15 non-allergics. Twenty-five participants attended first session (median Fel d 1=36.1 ng/m<sup>3</sup>) and 21 participants attended second session (median Fel d 1=102.0 ng/m<sup>3</sup>). Total nasal symptom scores (TNSS) for allergic participants in both sessions were not significantly different (p&lt;0.05) at any timepoint, hence results were combined. Allergic participants had significantly increased (p&lt;0.01) TNSS at all timepoints, from 15 minutes to 24 hours post-exposure, compared to non-allergics. Peak nasal inspiratory flow as percent change from baseline was significantly decreased (p&lt;0.05) for allergics compared to non-allergics from 1.0 to 2.5 hours. No clinically significant safety outcomes were reported in either session.</div></div><div><h3>Conclusion</h3><div>The SPaC-EEU can safely produce clinically relevant and meaningful nasal symptoms in only cat-allergic participants. We have proven that this facility is an effective and reliable clinical model for cat allergen-induced allergic rhinitis.</div></div>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"133 6","pages":"Page S17"},"PeriodicalIF":5.8000,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Allergy Asthma & Immunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1081120624006240","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

The Specialized Particulate Control Environmental Exposure Unit (SPaC-EEU) is a controlled allergen challenge facility that has recently undergone a successful technical validation for cat dander exposure, specifically Felis domesticus 1 (Fel d 1). We subsequently performed a clinical validation with cat-allergic and non-allergic participants.

Methods

Recruited participants attended a screening visit where eligibility was assessed. Successfully screened cat-allergic and non-allergic participants subsequently attended one of two 3-hour cat dander exposure sessions in the SPaC-EEU. Fel d 1 concentrations were determined using a Fel d 1-specific ELISA. Participants recorded symptom scores at 18 timepoints, between baseline and 24 hours post-onset of allergen exposure.

Results

Forty-five participants completed this study, 31 cat-allergics and 15 non-allergics. Twenty-five participants attended first session (median Fel d 1=36.1 ng/m3) and 21 participants attended second session (median Fel d 1=102.0 ng/m3). Total nasal symptom scores (TNSS) for allergic participants in both sessions were not significantly different (p<0.05) at any timepoint, hence results were combined. Allergic participants had significantly increased (p<0.01) TNSS at all timepoints, from 15 minutes to 24 hours post-exposure, compared to non-allergics. Peak nasal inspiratory flow as percent change from baseline was significantly decreased (p<0.05) for allergics compared to non-allergics from 1.0 to 2.5 hours. No clinically significant safety outcomes were reported in either session.

Conclusion

The SPaC-EEU can safely produce clinically relevant and meaningful nasal symptoms in only cat-allergic participants. We have proven that this facility is an effective and reliable clinical model for cat allergen-induced allergic rhinitis.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
专用微粒控制环境暴露单元(SPAC-EEU)对猫皮屑暴露的临床验证
导言专用微粒控制环境暴露装置(SPaC-EEU)是一种受控过敏原挑战设施,最近成功通过了猫皮屑(特别是家猫皮屑 1(Fel d 1))暴露的技术验证。我们随后对对猫过敏和不过敏的参与者进行了临床验证。通过筛查的猫过敏者和非过敏者随后参加了在 SPaC-EEU 进行的两个 3 小时猫皮屑暴露疗程中的一个疗程。使用 Fel d 1 特异性酶联免疫吸附法测定 Fel d 1 的浓度。参与者在 18 个时间点(从基线到接触过敏原后 24 小时)记录症状评分。结果45 名参与者完成了这项研究,其中 31 名猫过敏者,15 名非过敏者。25 名参与者参加了第一次治疗(中位数 Fel d 1=36.1 纳克/立方米),21 名参与者参加了第二次治疗(中位数 Fel d 1=102.0 纳克/立方米)。在两个疗程中,过敏性参与者的鼻部症状总分(TNSS)在任何时间点都没有显著差异(p<0.05),因此结果合并计算。与非过敏者相比,过敏者在暴露后 15 分钟至 24 小时的所有时间点上的 TNSS 都明显增加(p<0.01)。从 1.0 小时到 2.5 小时,与非过敏者相比,过敏者的峰值鼻吸气流量(与基线相比的百分比变化)明显下降(p<0.05)。结论 SPaC-EEU 可以安全地在对猫过敏的参与者中产生临床相关和有意义的鼻部症状。我们已经证明,该设备是猫过敏原诱发过敏性鼻炎的有效、可靠的临床模型。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.50
自引率
6.80%
发文量
437
审稿时长
33 days
期刊介绍: Annals of Allergy, Asthma & Immunology is a scholarly medical journal published monthly by the American College of Allergy, Asthma & Immunology. The purpose of Annals is to serve as an objective evidence-based forum for the allergy/immunology specialist to keep up to date on current clinical science (both research and practice-based) in the fields of allergy, asthma, and immunology. The emphasis of the journal will be to provide clinical and research information that is readily applicable to both the clinician and the researcher. Each issue of the Annals shall also provide opportunities to participate in accredited continuing medical education activities to enhance overall clinical proficiency.
期刊最新文献
From the Pages of AllergyWatch. How best to choose an oscillometer and reference equations for your patients with asthma. Oscillometry-defined small airways dysfunction as a treatable trait in asthma. Analyzing Phenotypes Post-Exposure in Allergic Rhinitis (APPEAR) in the Environmental Exposure Unit (EEU). Perturbations in the airway microbiome are associated with type 2 asthma phenotype and severity.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1